Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?

Over the last decade, several steps forward in the treatment of patients with stage IV non-small cell lung cancer (NCSLC) were made. Examples are the use of pemetrexed, pemetrexed maintenance therapy, or bevacizumab for patients with nonsquamous NSCLC. A big leap forward was the use of tyrosine kina...

Descripción completa

Detalles Bibliográficos
Autores principales: Deslypere, Griet, Gullentops, Dorothée, Wauters, Els, Vansteenkiste, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949924/
https://www.ncbi.nlm.nih.gov/pubmed/29774061
http://dx.doi.org/10.1177/1758835918772810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949924/
https://www.ncbi.nlm.nih.gov/pubmed/29774061
http://dx.doi.org/10.1177/1758835918772810

Ejemplares similares